US2021046093A1PendingUtilityA1
Optimizing Mifepristone Absorption
Est. expiryNov 18, 2031(~5.3 yrs left)· nominal 20-yr term from priority
A61K 31/567A61K 31/575
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of improving absorption of mifepristone in a patient suffering from Cushing's Syndrome, comprising administering to the patient for at least 7 days an oral dose of mifepristone of 900 mg per day within about 30 minutes after consuming a meal, such that the pharmacokinetics of mifepristone absorption are altered by increasing the maximum plasma concentration (C max ) and increasing the area under the curve (AUC) as compared to the C max and AUC that would result from administering mifepristone without food in the fasted state in the absence of the meal, said increase in AUC being at least 44%, and thereby improving mifepristone absorption in the patient.
2 . The method of claim 1 , wherein the patient suffers from Cushing's disease.
3 . The method of claim 1 , wherein the daily oral dose of mifepristone is administered for at least 28 days.
4 . The method of claim 1 , wherein the mifepristone is administered as a single dose.
5 . The method of claim 1 , wherein the increase in AUC is at least 65%.
6 . The method of claim 1 , wherein the increase in C max is at least 34%.
7 . The method of claim 1 , wherein the increase in C max is at least 56%.
8 . The method of claim 5 , wherein the increase in C max is at least 34%.
9 . The method of claim 5 , wherein the increase in C max is at least 56%.
10 . The method of claim 1 , wherein the patient is a male.
11 . The method of claim 1 , wherein the patient is a female.Join the waitlist — get patent alerts
Track US2021046093A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.